Physician profile
Frederick Potulski
NPI 1659373439
$7,245.30
in general payments reported to CMS, 2019-2025
30 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $200 · 2021: $605 · 2022: $1,520 · 2023: $1,641 · 2024: $1,233 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,224.78 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,328.12 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $760.98 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $554.87 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $460.23 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $441.54 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $249.31 | 2019-2024 | Yupelri |
| Amgen INC. | $219.03 | 2022-2025 | Tezspire |
| Viatris Specialty LLC | $146.33 | 2025 | Yupelri |
| United Therapeutics Corporation | $98.83 | 2022-2025 | Tyvaso, Tyvaso, Orenitram |
| Baxter Healthcare | $89.15 | 2023-2025 | Hillrom - Life 2000 Ventilation System |
| Inspire Medical Systems, INC. | $72.04 | 2023-2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $70.18 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $61.51 | 2019-2023 | Uptravi |
| Grifols USA, LLC | $56.45 | 2025 | Prolastin-C Liquid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $51.77 | 2022-2025 | Aralast |
| Insmed, INC. | $45.83 | 2019-2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $45.80 | 2022 | |
| Verona Pharma, INC. | $45.23 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $44.97 | 2022-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $28.63 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $28.25 | 2022 | |
| Axsome Therapeutics, INC. | $17.27 | 2025 | Sunosi |
| Ani Pharmaceuticals, INC. | $16.84 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $15.69 | 2023 | Xolair |
| Melinta Therapeutics, LLC | $14.93 | 2019 | |
| Horizon Therapeutics Plc | $14.65 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.10 | 2021 | |
| Circassia INC. | $14.09 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.90 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Potulski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.